Johnson & Johnson (NYSE: JNJ) reported its third quarter 2024 earnings outcomes as we speak.
Reported gross sales elevated 5.2% year-over-year to $22.5 billion.
GAAP earnings decreased 37.5% to $2.7 billion whereas EPS fell 34% to $1.11 in comparison with final 12 months. Adjusted EPS was down 9% to $2.42.
For full-year 2024, JNJ expects reported gross sales of $88.4-88.8 billion and adjusted EPS of $9.88-9.98.
(This story can be up to date shortly with an infographic)
It’s one factor after I speak about a coming AI-driven singularity. However when the Federal Reserve begins speaking about it, you...
In an era where smartphones are central to modern life, "battery anxiety" has become a universal challenge. Power bank sharing,...
When Meta Platforms, Inc. (NASDAQ: META) reviews its third-quarter outcomes, buyers will likely be searching for updates on the trajectory...
Lauren Taylor Wolfe, co-founder of activist funding agency Impactive Capital, stated the surge in enthusiasm round synthetic intelligence has all...
The CBOE Volatility Index, in any other case often called the Wall Road's concern gauge, is coming off its most...
Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.
